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BACKGROUND: The N-terminal fragment of pro-brain type natriuretic peptide (NT-proBNP) is an established
biomarker for cardiac failure.
OBJECTIVE: To determine the influence of preoperative serum NT-proBNP on postoperative outcome and mid-term
survival in patients undergoing coronary artery bypass grafting (CABG).
METHODS: In 819 patients undergoing isolated CABG surgery preoperative serum NT-proBNP levels were measured.
NT-proBNP was correlated with various postoperative outcome parameters and survival rate after a median follow-
up time of 18 (0.5–44) months. Risk factors of mortality were identified using x2, Mann–Whitney test, and Cox
regression.
RESULTS: NT-proBNP levels .430 ng/ml and .502 ng/ml predicted hospital and overall mortality (p,0.05), with an
incidence of 1.6% and 4%, respectively. Kaplan–Meier analysis revealed decreased survival rates in patients with NT-
proBNP .502 ng/ml (p =0.001). Age, preoperative serum creatinine, diabetes, chronic obstructive pulmonary
disease, low left ventricular ejection fraction and BNP levels .502 ng/ml were isolated as risk factors for overall
mortality. Multivariate Cox regression analysis, including the known factors influencing NT-proBNP levels, identified
NT-proBNP as an independent risk factor for mortality (OR=3.079 (CI = 1.149-8.247), p = 0.025). Preoperative NT-
proBNP levels .502 ng/ml were associated with increased ventilation time (p=0.005), longer intensive care unit stay
(p= 0.001), higher incidence of postoperative hemofiltration (p=0.001), use of intra-aortic balloon pump (p,0.001),
and postoperative atrial fibrillation (p=0.031)
CONCLUSION: Preoperative NT-proBNP levels .502 ng/ml predict mid-term mortality after isolated CABG and are
associated with significantly higher hospital mortality and perioperative complications.
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INTRODUCTION
Brain type natriuretic peptide (BNP) is primarily pro-
duced by cardiac myocytes. Physiological effects of BNP
are a peripheral vasodilatation and inhibition of renin–
angiotensin production.1-3 The precursor peptide proBNP
is split into the active hormone BNP and the N-terminal
fragment of proBNP (NT-proBNP). Both BNP and NT-
proBNP are established markers for cardiac failure.
However, other pathologies such as exacerbated chronic
obstructive pulmonary disease, acute coronary syndromes,
atrial fibrillation, and myocarditis can cause elevated BNP
levels. Additionally, higher NT-proBNP levels are asso-
ciated with: female gender, impaired renal function, and
older age. Obesity has been shown to decrease NT-proBNP
levels.2 Increased BNP levels are a prognostic marker
associated with higher mortality in patients with myocardial
infarction, cardiogenic shock, and pulmonary embolism.4-6
In patients with coronary artery disease increased BNP
levels are associated with an increased rate of myocardial
infarction and cardiovascular death during mid-term
follow-up.7
We aimed to investigate if preoperative serum NT-
proBNP levels are associated with hospital and mid-term
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mortality and with postoperative outcome variables in
patients undergoing isolated coronary artery bypass graft-
ing (CABG)
PATIENTS AND METHODS
Data used in the analysis were collected from the
institutional database at the Department of Cardiac
Surgery, Innsbruck Medical University, which contained
data collected using the data collection form of the Society of
Thoracic Surgeons (Adult Cardiac Surgery Database Data
Collection form Version 2.25.1). Preoperative NT-proBNP
was measured routinely in all patients on the day of
admission before surgery. The data of 819 patients under-
going isolated CABG were analysed. Patients included in
the study were consecutive cases with CABG seen at our
department between 2001 and 2007. Patients with concomi-
tant procedures (valve surgery, aortic surgery, etc) were
excluded. Patients with missing preoperative NT-proBNP
values were also excluded. Patients were followed up by
request of the national death registry (Statistik Austria).
Definitions
Primary end points of the study included:
Hospital mortality, defined as the incidence of death
occurring during admission to hospital for surgery or up
to 30 days after CABG
Overall mortality, defined as hospital deaths and all deaths
during the follow-up time.
Secondary end points of the study were:
Carotid artery disease, defined as the presence of carotid
artery stenosis of $50%, or carotid artery occlusion, or post-
carotid endarterectomy.
The EuroSCORE, used for perioperative risk stratification
as described by Nashef and coworkers.8
Hypertension, diagnosed if current blood pressure was
.140 mmHg systolic or .90 mmHg diastolic, or if the
patient was currently receiving antihypertensive drugs, or if
the patient had a history of hypertension.
Stroke, defined as any neurologic impairment of motor,
sensory or cognitive function that persisted for .24 h, or
was associated with death, and that could not be explained
by other neurologic etiologies (ie, postoperative delirium,
dementia, head trauma).
History of neurologic events, defined as a preoperative
history of transient ischemic attack or stroke.
Chronic obstructive pulmonary disease (COPD), defined by
long-term use of bronchodilators or steroids for lung disease
and forced expiratory volume in one second (FEV1),80% of
the predicted value in preoperative spirometry, which was
performed routinely at our clinic.
Peripheral vascular disease, defined as the presence of
intermittent claudication, or previous or planned interven-
tion on the abdominal aorta or limb arteries.
Ventilation time, defined as the duration of ventilation
needed postoperatively, including potential need for addi-
tional ventilation after re-intubation.
Intensive care unit (ICU) stay, defined as the duration of
ICU stay needed after the operation, including potential
need for additional ICU stay after readmission.
Perioperative myocardial infarction, defined as the develop-
ment of new persistent ST-segment, T- or Q-wave changes
in electrocardiogram (ECG), new left bundle branch block,
and/or troponin T elevation above the 5699th centile of the
upper reference limit and/or creatine kinase (CK)-MB/CK
ratio of .10%.
Need for intra-aortic balloon pump (IABP), defined as any
use of an IABP after establishing cardiopulmonary bypass
or in the postoperative period.
Postoperative atrial fibrillation, defined as any new episode
of atrial fibrillation documented by online monitoring or on
ECG during the postoperative period.
Reoperation for bleeding, defined as any incidence of
reoperation needed for bleeding complications.
Statistical Analysis
Continuous variables are shown as median and range,
categorical variables as number and percentage. The 1-, 2-,
and 3-year survival rates were calculated using a life table.
We calculated the best cut-off values of NT-proBNP to
predict hospital mortality or overall mortality by using
receiver operating characteristic (ROC) curves. The compar-
ison between categorical variables and hospital mortality,
overall death, or NT-proBNP .502 ng/l was performed
using x2 analysis. The comparison between continuous
variables and hospital mortality, overall death, or NT-
proBNP .502 ng/l was performed using a Mann–Whitney
test. Survival curves were generated using Kaplan–Meier
estimates. Differences in the survival rate were calculated
using the log rank test. For multivariate analysis we used a
Cox regression model. As covariates the factors commonly
known to influence NT-proBNP levels were entered:
gender, age (we chose an age .67 years, which was the
median of our cohort), body mass index (calculated as
body weight [kg]/height2 [m2]; we chose a BMI .27 kg/m2,
which was the median of our cohort), serum creatinine
levels above the upper reference limit of 1.2 mg/dl. A p
value ,0.05 was regarded as statistically significant.
SPSSTM 15.0 for Windows (SPSS Inc, Chicago, USA) statis-
tical software was used.
RESULTS
After a median follow up time of 18 (0.5–44) months 33/
819 (4%) patients died, including 13/819 (1.6%) hospital
deaths. The 1, 2-, and 3-year survival rates (including
hospital mortality) were 97%, 93%, and 90%, respectively.
Analysis of the ROC curves showed that a serum NT-
proBNP cut-off level of 430 ng/l best predicted hospital
mortality and a cut-off level of 502 ng/l best predicted
overall mortality (Figure 1). Univariate analysis showed that
age, preoperative serum creatinine, peripheral vascular
disease, and NT-proBNP levels .430 ng/l were signifi-
cantly associated with hospital mortality. Age, preoperative
serum creatinine, diabetes mellitus, history of cerebrovas-
cular accident, chronic obstructive pulmonary disease, left
ventricular ejection fraction, and NT-proBNP levels
.502 ng/l were significantly associated with overall
mortality (Tables 1 and 2).
The Kaplan–Meier analysis confirmed a significantly
decreased survival rate of patients with NT-proBNP levels
.502 ng/l (n = 306) compared with NT-proBNP levels
#502 ng/l (n = 513) (p = 0.001, Figure 2) The 1, 2-, and 3-
year survival rates (including hospital mortality) were 98%,
96%, and 92%, respectively, if NT-proBNP levels were
#502 ng/l vs. 94%, 87%, and 87%, respectively, if NT-
proBNP levels were .502 ng/l.
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Figure 1 - Receiver operating characteristic curve of N-terminal pro-brain type natriuretic peptide (NT-proBNP) level predicting overall
death.
Table 1 - Univariate correlations between demographical data of 819 coronary artery bypass patients and hospital
mortality and mid-term mortality.
Hospital mortality
(p values)
Hospital
mortality (RR)
Overall death
(p values)
Overall
death (RR)
Male gender 0.176 2.11 (0.7–6.39) 0.059 1.93 (0.97–3.85)
Chronic renal failure requiring dialysis 0.736 0.166 0.28 (0.04–1.75)
History of smoking 0.924 1.06 (0.33–3.4) 0.582 0.82 (0.41–1.65)
Current smoker 0.480 0.912
Diabetes mellitus 0.910 1.08 (0.3–3.76) 0.014 0.44 (0.22–0.86)
Insulin-dependent diabetes mellitus 0.349 0.030 0.37 (0.15–0.92)
Family history of coronary artery disease 0.152 0.44 (0.14–1.4) 0.203 0.606 (0.28–1.31)
Arterial hypertension 0.960 1.039 (0.23–4.63) 0.966 1.020 (0.40–2.59)
Dyslipidemia 0.444 0.463 (0.06–3.53) 0.332 1.495 (0.66–3.37)
History of cerebrovascular accident 0.471 na ,0.001 0.220 (0.09–0.53)
Chronic obstructive pulmonary disease 0.073 0.377 (0.124–1.141) 0.04 0.50 (0.26–0.98)
Peripheral vascular disease 0.046 0.324 (0.10–1.03) 0.127 0.534 (0.24–1.2)
Carotid artery disease 0.339 na 0.412 2.21 (0.31–15.89)
History of myocardial infarction 0.204 0.5 (0.16–1.5) 0.053 0.52 (0.26–1.02)
Previous percutaneous coronary intervention 0.515 0.61 (0.14–2.17) 0.680 0.80 (0.29–2.24)
Urgent operation 0.430 0.6 (0.17–2.15) 0.634 0.81 (0.34–1.42)
Reoperation for bleeding ,0.001 0.05 (0.02–0.17) ,0.001 0.14 (0.05–0.38)
Perioperative myocardial infarction ,0.001 0.04 (0.01–0.23) ,0.001 0.06 (0.02–0.28)
Perioperative stroke ,0.001 0.44 (0.01–0.46) 0.033 0.12 (0.01–1.21)
Postoperative transient ischemic attack 0.857 1.01 (1.00–1.03) 0.772 1.04 (1.03–1.06)
Postoperative renal failure ,0.001 0.022 (0.01–0.07) ,0.001 0.04 (0.02–0.1)
Postoperative atrial fibrillation 0.525 1.63 (0.36–7.40) 0.831 0.92 (0.41–2.06)
Sternal wound infections 0.620 1.02 (1.01–1.03) 0.423 1.04 (1.03–1.06)
Intraoperative blood products 0.029 0.30 (0.1–0.94) 0.251 0.66 (0.33–1.35)
NT-proBNP serum level .430 ng/l 0.036 0.31 (0.1–0.99) ,0.001 0.22 (0.10–0.49)
NT-proBNP serum level .502 ng/l 0.216 0.51 (0.17–1.51) ,0.001 0.3 (0.15–0.60)
NT-proBNP; N-terminal pro-brain type natriuretic peptide; RR, relative risk.
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Mortality According to Quartiles of Serum
NT-proBNP levels
Incidence of death during follow-up was significantly
higher in the highest (18/205) in comparison with the lowest
NT-proBNP quartile (1/203), (p,0.001, Table 3). Cox regres-
sion analysis of the different quartiles of NT-proBNP also
showed significant differences. (p,0.001, Figure 3)
Multivariate Cox regression analysis (covariates: gender,
age .67 years, BMI .27 kg/m2, serum creatinine .1.2 mg/
dl) revealed NT-proBNP as an independent risk factor for
mid-term survival (p = 0.025, OR = 3.079, CI = 1.149–8.247).
Association Between NT-proBNP Levels and
Perioperative Outcome
Patients with NT-proBNP levels .502 ng/l had more
comorbidities and consecutively a higher EuroSCORE than
those with NT-proBNP levels #502 ng/l. Postoperatively
those patients had a significantly longer ventilation time
(p = 0.005), longer ICU stay (p = 0.001), a higher rate of renal
failure requiring hemofiltration (p = 0.001), a higher rate of
Table 2 - Statistical differences between patients who are alive or dead at discharge and at time of follow-up.
Discharge alive Discharge dead p Value Alive at follow-up Dead at follow-up p Value
Age (years) 67 (27–89) 76 (55–80) 0.022 67 (27–89) 76 (55–80) 0.011
Body mass index (kg/m2) 27 (18–55) 26 (20–36) 0.573 27 (18–55) 26 (19–40) 0.886
Preoperative serum creatinine (mg/dl) 1.0 (0.5–6.2) 1.2 (0.7–2.0) 0.024 1 (0.5–6.2) 1.1 (0.7–5.0) 0.018
Left ventricular ejection fraction (%) 51 (10–91) 54 (25–70) 0.716 53 (10–91) 50 (20–70) 0.008
Logarithmic EuroSCORE 3 (0–63) 5 (2–63) 0.092 3 (0–52) 5 (1–63) 0.003
Linear EuroSCORE 4 (0–17) 5 (1–11) 0.092 4 (0–15) 6 (0–17) 0.008
Total number of distal coronary anastomoses 3 (1–6) 3 (1–5) 0.773 3 (1–6) 3 (1–5) 0.580
Cardiopulmonary bypass time (min) 103 (0–428) 113 (0–355) 0.597 103 (0–428) 104 (0–355) 0.749
Aortic cross-clamping time (min) 57 (0–345) 64 (0–127) 0.986 57 (0–345) 58 (0–127) 0.809
Total mechanical ventilation time (h) 8 (0–1,900) 19 (7–482) ,0.001 8 (0–776) 18 (4–1,900) ,0.001
Total time on ICU (h) 21 (1–1,919) 58 (7–1,012) ,0.001 21 (1–1,268) 45 (7–1,919) ,0.001
Figure 2 - Survival rate of coronary artery bypass patients with preoperative serum N-terminal pro-brain type natriuretic peptide (NT-
proBNP) levels . 502 ng/l compared with NT-proBNP levels , 502 ng/l.
Table 3 - Overall death rate (n= 33) of 819 coronary artery
bypass patients grouped according to quartiles of
serum N-terminal pro-brain type natriuretic peptide
(NT-proBNP) levels.
Quartile NT-pro-BNP (ng/l) n deaths
1 66 (6–122) 203 1
2 194 (123–291) 207 6
3 502 (296–808) 204 8
4 1704 (810–65,998) 205 18
The difference between the groups was statistically significant (p,0.001).
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IABPs (p,0.001), and a higher rate of postoperative atrial
fibrillation (p = 0.031) than patients with NT-proBNP levels
#502 ng/l (Table 4).
DISCUSSION
NT-proBNP and Hospital Mortality
In our series ROC curve analysis revealed an NT-proBNP
cut-off level of 430 ng/l to best predict hospital mortality
and a cut-off level of 502 ng/l for prediction of overall
mortality. These levels are comparable to cut-off levels for
predicting postoperative cardiac events in patients under-
going vascular surgery, which were reported to be between
280 and 533 pg/ml.1 Nozohoor et al. found that an increased
BNP level on admission to the ICU was a risk factor for
heart failure following aortic valve replacement.9
Nevertheless, one has to keep in mind that cut-off points
vary between different study cohorts. Thus we focused on
patients undergoing isolated CABG surgery in our study.
We found that age, preoperative serum creatinine,
peripheral vascular disease, and NT-proBNP levels
.430 ng/l were significantly associated with hospital
mortality. Although the first three risk factors are also
found to be predictive for hospital mortality in the
EuroSCORE, NT-proBNP is not part of this preoperative
risk score for cardiac surgery patients.8 In an interesting
study, Grabowski et al. found a higher early mortality and a
decreased PCI success rate (especially an increased number
of no-reflow phenomenon) in patients with acute ST
elevation myocardial infarction and with high levels of
serum BNP.4
NT-proBNP and Mid-term Survival Rates
In a series of 98 male patients undergoing different types of
heart surgery Hutfless et al. found increased BNP levels in
patients who died within 1 year after surgery.10 Kragelund et
al. found a decreased long-term survival in 1039 patients with
stable coronary artery disease and increased BNP levels.11
Other authors found that BNP and NT-proBNP levels were
predictive for survival rates in patients with acute coronary
syndromes and acute myocardial infarction.12,13 In our study,
mid-term survival rates were significantly decreased in
patients with elevated NT-proBNP levels. Furthermore, NT-
proBNP remained as a significant risk factor of survival when
the commonly known factors influencing BNP levels (ie,
gender, age BMI, serum creatinine) were included in the
multivariate analysis.
NT-proBNP and Postoperative Complications
We found an increased mechanical ventilation time and
length of ICU stay in patients with elevated preoperative
NT-proBNP levels. In general, those patients exhibited a
higher rate of comorbidities, resulting in an increased risk
score (EuroSCORE). In detail, a higher rate of postoperative
renal failure requiring hemofiltration was found, which may
be explained by the higher preoperative serum creatinine
levels in patients with NT-proBNP levels .502 ng/ml. We
also found a higher rate of IABPs associated with higher
NT-proBNP levels. This is in good agreement with Hutfless
et al., who reported higher BNP levels in patients requiring
an IABP postoperatively compared with those who did
not.10 In exacerbated COPD elevated BNP levels were
associated with a prolonged stay in the ICU.14
Figure 3 – Mid- term survival of coronary artery bypass patients stratified by quartiles of preoperative N-terminal pro-brain type
natriuretic peptide (NT-proBNP) levels.
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Atrial fibrillation is a common complication after cardiac
surgery. Although it is easily manageable, it causes a
(transient) circulatory disturbance that may be critical for
the intensive care patient. In our study we found a higher
rate of postoperative atrial fibrillation in patients with
elevated NT-proBNP levels. Wazni and coworkers found
that patients with atrial fibrillation following cardiac
surgery exhibited higher BNP levels than patients who
remained in sinus rhythm throughout the postoperative
course.15
Clinical impact of the study
Preoperative measurement of NT-proBNP levels can be
used, in addition to established risk scores, to determine
CABG patients with an increased risk. Since the mid-term
survival following coronary bypass surgery is significantly
decreased, patients with increased NT-proBNP should be
followed up closely. In accordance with this, Mayer et al.
recently published results showing a decreased long-term
survival rate of coronary patients without clinical manifes-
tation of heart failure and NT-proBNP levels.862 pmol/l.16
We conclude that elevated preoperative serum NT-
proBNP levels are associated with a higher postoperative
early and mid-term mortality, as well as morbidity, in
patients undergoing isolated CABG.
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